Cross-over Study on Effect of Lipid Lowering by Acipimox on Cardiac and Skeletal Muscle Mitochondrial Function

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

31 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-03-31

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Accumulation of lipid in skeletal and cardiac muscle has been associated with insulin resistance and diabetic cardiomyopathy. In skeletal muscle, lipotoxic damage has been suggested to lead to dysfunction of mitochondria. It remains unknown whether lipotoxicity leads to mitochondrial dysfunction in heart as well, and if so, whether this also leads to cardiomyopathy (failure of the heart). Although it has been shown that lipid lowering agents can improve insulin sensitivity, the effect of lowering free fatty acids on cardiac and skeletal muscle mitochondrial function remains unknown. In this study the investigators want to investigate whether lowering cardiac and muscular lipid content will improve mitochondrial and cellular function in type 2 diabetic patients.

To this end, type 2 diabetic patients and body mass index (BMI)-matched controls will be included in a blinded cross-over design, in which subjects will receive a lipid lowering agent (Acipimox) or placebo for 2 weeks in random order. During treatment, diabetes medication will be stopped. Baseline measurements will be performed prior to the study and after each treatment to assess cardiac and muscular lipid accumulation, cardiac function, mitochondrial function and insulin sensitivity.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Assess the Drug-Drug Interaction Between Bedaquiline and Clarithromycin in Healthy Adult Participants

NCT03800550

Healthy

COMPLETED PHASE1

Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s

NCT03457597

Healthy

COMPLETED PHASE1

Pharmacokinetic Interaction Between AZD3480 and Donepezil

NCT00713765

Alzheimer's Disease

TERMINATED PHASE1

Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)

NCT03067441

Hypercholesterolemia Atherosclerotic Cardiovascular Disease

COMPLETED PHASE3

Drug-drug Interaction Study of KL1333 in Healthy Subjects

NCT04643249

Mitochondrial Disease

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 2 Cardiomyopathy, Dilated

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Acipimox

Subjects will receive Acipimox or a placebo in random order. Acipimox is a commercially available and registrated drug, that lowers free fatty acids by inhibiting hormone sensitive lipase in the peripheral adipose tissue. No serious side-effects are known other than rare anaphylactic reactions.

Group Type EXPERIMENTAL

Acipimox

Intervention Type DRUG

A capsula is given with 250mg Acipimox, 3dd; 1 after each meal. This will be done during 14 days.

Cellulosum mycrocryst capsula

Subjects will receive Acipimox or a placebo in random order. Acipimox is a commercially available and registrated drug, that lowers free fatty acids by inhibiting hormone sensitive lipase in the peripheral adipose tissue. No serious side-effects are known other than rare anaphylactic reactions.

Group Type PLACEBO_COMPARATOR

Cellulosum Mycrocryst

Intervention Type DRUG

Capsule with cellulosum powder; this has to be taken 3 dd; 1 after each meal during 14 days.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Acipimox

A capsula is given with 250mg Acipimox, 3dd; 1 after each meal. This will be done during 14 days.

Intervention Type DRUG

Cellulosum Mycrocryst

Capsule with cellulosum powder; this has to be taken 3 dd; 1 after each meal during 14 days.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Olbetam Nedios Placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or postmenopausal females
* Age 40-70 years
* Obese (BMI \> 30 kg/m2), non-insulin dependent type 2 diabetic patients and BMI matched control subjects without diabetes.
* Generally healthy with specifically no known cardiovascular disease, dyslipidemia, or gastric ulcers (contra-ind. of Acipimox), which can affect the study parameters.
* Must be on sulphonylurea(SU)- derivate or metformin therapy for at least six months with a constant dose for at least two months, or on dietary treatment for at least six months
* Well-controlled diabetes: HbA1c\<8%.
* Control subjects must have a plasma glucose lower than 6,1 mmol/L.
* Stable dietary habits (no weight loss/gain \> 3 kg in the last 6 months)

Exclusion Criteria

* Known cardiovascular disease, dyslipidemia, hepatic or renal failure and gastric ulcers.
* Insulin dependent Diabetic patients.
* Use of lipid lowering agents, except from Statins, as these do not affect triglycerides levels (with exception to Lipitor).
* Use of Thiazolidines (glitazone/rosiglitazone/pioglitazone/troglitazone)
* Use of anti-coagulants (not thrombocyte-aggregation inhibitors)
* Aberrant ECG (with signs of ischemia or cardiac failure or arrythmia's)
* Weight gain/loss \> 3 kg in the last 6 months.
* Hb \< 7,3 in women, and \< 7,8 in men.
* Contraindications for MRI scans:

* Electronic implants such as pacemakers or neurostimulator
* Iron-containing corpora aliena in eyes or brain
* Some hearing aids and artificial (heart) valves which are contraindicated for MRS
* Claustrophobia
* Subjects, who do not want to be informed about unexpected medical findings, or do not wish that their physician is informed, cannot participate in the study.

Minimum Eligible Age

40 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes